Serum irisin levels in new-onset type 2 diabetes.
OBJECTIVE
Irisin has been identified as a novel myokine that drives brown-fat-like conversion of white adipose tissue. In this cross-sectional study, we investigated whether serum irisin levels are decreased in patients with type 2 diabetes (T2D) compared with control subjects with normal glucose tolerance (NGT), and assessed the association between serum irisin levels and various metabolic parameters.


METHODS
The study population was selected from a population-based study and included 104 subjects with NGT and 104 subjects with new-onset T2D. Serum irisin and adiponectin levels and metabolic parameters were measured. Multivariate logistic regression analysis was performed to assess the association between irisin levels and newly diagnosed T2D.


RESULTS
Serum irisin levels were significantly decreased in the new-onset T2D group compared with the NGT control group (p=0.003). In a multivariable model adjusted for various metabolic parameters, increased irisin levels were associated with reduced odds (OR 0.64, 95% CI 0.47-0.88, p=0.006) of prevalent newly diagnosed T2D. Furthermore, multiple regression analysis showed that 2 h plasma glucose was an independent variable influencing serum irisin levels (p=0.004).


CONCLUSIONS
In the present study, we found that serum irisin levels were decreased in T2D patients and inversely associated with newly diagnosed T2D, suggesting that irisin may play a crucial role in glucose intolerance and T2D.
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea.
Yeon-Kyung
YK
Choi
Mi-Kyung
MK
Kim
Kwi Hyun
KH
Bae
Hyun-Ae
HA
Seo
Ji-Yun
JY
Jeong
Won-Kee
WK
Lee
Jung-Guk
JG
Kim
In-Kyu
IK
Lee
Keun-Gyu
KG
Park
D052242:Adiponectin / Q000097:blood*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D005353:Fibronectins / Q000097:blood; D006801:Humans; D016015:Logistic Models; D008297:Male; D009765:Obesity / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D047495:PPAR gamma / Q000097:blood; D000071248:Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; D056910:Republic of Korea / Q000453:epidemiology; D022722:Thermogenesis; D014157:Transcription Factors / Q000097:blood
D052242:Adiponectin; D015415:Biomarkers; C577593:FNDC5 protein, human; D005353:Fibronectins; D047495:PPAR gamma; C486497:PPARGC1A protein, human; D000071248:Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; D014157:Transcription Factors